|
PT2931738T
(pt)
|
2012-12-13 |
2019-04-10 |
Aduro Biotech Inc |
Composições compreendendo nucleótidos cíclicos de purina com estereoquímica definida e métodos para a sua preparação e utilização
|
|
EP4398254A3
(en)
|
2013-04-29 |
2024-10-23 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for altering second messenger signaling
|
|
US20140329889A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
|
US9549944B2
(en)
|
2013-05-18 |
2017-01-24 |
Aduro Biotech, Inc. |
Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
|
|
PT2996473T
(pt)
|
2013-05-18 |
2019-11-18 |
Univ California |
Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
|
|
US10176292B2
(en)
|
2013-07-31 |
2019-01-08 |
Memorial Sloan-Kettering Cancer Center |
STING crystals and modulators
|
|
CR20160564A
(es)
|
2014-06-04 |
2017-01-20 |
Glaxosmithkline Ip Dev Ltd |
Dinucleótidos cíclicos como moduladores de sting
|
|
GB201501462D0
(en)
|
2015-01-29 |
2015-03-18 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
HK1248603A1
(zh)
|
2015-03-10 |
2018-10-19 |
Aduro Biotech, Inc. |
用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
SG10202010609QA
(en)
|
2015-08-13 |
2020-11-27 |
Merck Sharp & Dohme |
Cyclic di-nucleotide compounds as sting agonists
|
|
RU2020113165A
(ru)
|
2015-12-03 |
2020-06-09 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Циклические пуриновые динуклеотиды в качестве модуляторов sting
|
|
CN109451740B
(zh)
|
2016-01-11 |
2022-09-02 |
先天肿瘤免疫公司 |
用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸
|
|
EP3692996A1
(en)
*
|
2016-03-18 |
2020-08-12 |
Immune Sensor, LLC |
Cyclic di-nucleotide compounds and methods of use
|
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
|
IL295649B2
(en)
*
|
2016-04-07 |
2025-12-01 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides useful as protein modulators
|
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
|
|
CA3029644A1
(en)
|
2016-07-06 |
2018-01-11 |
Sperovie Biosciences, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
|
MA46452B1
(fr)
|
2016-10-04 |
2021-10-29 |
Merck Sharp & Dohme |
Composés de benzo[b]thiophéne en tant qu'agonistes de sting
|
|
WO2018065360A1
(de)
|
2016-10-07 |
2018-04-12 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh |
Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen
|
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
JP7275031B2
(ja)
*
|
2017-01-27 |
2023-05-17 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
|
|
CN110234404A
(zh)
|
2017-01-27 |
2019-09-13 |
詹森生物科技公司 |
作为sting激动剂的环状二核苷酸
|
|
JP2018131427A
(ja)
*
|
2017-02-17 |
2018-08-23 |
国立研究開発法人理化学研究所 |
免疫細胞の制御技術
|
|
US20200055883A1
(en)
|
2017-02-17 |
2020-02-20 |
Eisai R&D Management Co., Ltd. |
Cyclic di-nucleotides derivative for the treatment of cancer
|
|
JP7591348B2
(ja)
|
2017-02-21 |
2024-11-28 |
ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム |
インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
|
|
EA036338B1
(ru)
*
|
2017-02-22 |
2020-10-28 |
Глэксосмитклайн Интеллекчуал Проперти Девелопмент Лимитед |
Гетероциклические амиды, пригодные в качестве модуляторов белков
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
EP3609922A2
(en)
|
2017-04-13 |
2020-02-19 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
|
WO2018198084A1
(en)
*
|
2017-04-27 |
2018-11-01 |
Lupin Limited |
Cyclic di-nucleotide compounds with tricyclic nucleobases
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
EP3621624B1
(en)
|
2017-05-12 |
2023-08-30 |
Merck Sharp & Dohme LLC |
Cyclic di-nucleotide compounds as sting agonists
|
|
US11969499B2
(en)
|
2017-06-16 |
2024-04-30 |
William Marsh Rice University |
Hydrogel delivery of sting immunotherapy for treatment cancer
|
|
ES2932354T3
(es)
*
|
2017-07-28 |
2023-01-18 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticáncer
|
|
CA3071538A1
(en)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
Benzo[b]thiophene sting agonists for cancer treatment
|
|
AU2018311965A1
(en)
|
2017-08-04 |
2020-02-13 |
Merck Sharp & Dohme Llc |
Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
|
|
TWI808092B
(zh)
|
2017-08-30 |
2023-07-11 |
中國大陸商北京軒義醫藥科技有限公司 |
作為干擾素基因調節劑之刺激劑的環狀二核苷酸
|
|
EP3675859A4
(en)
|
2017-08-31 |
2021-06-30 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
|
|
US11667663B2
(en)
*
|
2017-08-31 |
2023-06-06 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
WO2019051488A1
(en)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
|
|
US11707531B2
(en)
|
2017-09-11 |
2023-07-25 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
JP7262451B2
(ja)
*
|
2017-10-05 |
2023-04-21 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Ｓｔｉｎｇアゴニストの投与方法
|
|
JP7291130B2
(ja)
*
|
2017-10-05 |
2023-06-14 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
|
|
EP3692033A1
(en)
*
|
2017-10-05 |
2020-08-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (sting) useful in treating hiv
|
|
CN109694397B
(zh)
*
|
2017-10-23 |
2021-08-31 |
上海弘翊生物科技有限公司 |
环状二核苷酸化合物、其制备方法和应用
|
|
SG11202004113VA
(en)
*
|
2017-11-10 |
2020-06-29 |
Takeda Pharmaceuticals Co |
Sting modulator compounds, and methods of making and using
|
|
AU2018392212B9
(en)
*
|
2017-12-20 |
2021-03-18 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
AU2018392213B2
(en)
|
2017-12-20 |
2021-03-04 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
CN110016025B
(zh)
*
|
2018-01-08 |
2021-08-06 |
成都先导药物开发股份有限公司 |
一种免疫调节剂
|
|
CN110016021B
(zh)
*
|
2018-01-08 |
2021-05-07 |
成都先导药物开发股份有限公司 |
一种免疫调节剂
|
|
US12220462B1
(en)
|
2018-02-13 |
2025-02-11 |
Abionyx Pharma Sa |
Complexes for delivery of cyclic dinucleotides
|
|
US10519187B2
(en)
*
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
EP3755331B1
(en)
|
2018-02-21 |
2026-01-28 |
The Scripps Research Institute |
Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer
|
|
TWI741268B
(zh)
*
|
2018-03-15 |
2021-10-01 |
美商輝瑞股份有限公司 |
干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
|
|
US20210015915A1
(en)
|
2018-03-23 |
2021-01-21 |
Takeda Pharmaceutical Company Limited |
Sting modulator compounds with sulfamate linkages, and methods of making and using
|
|
IL309265A
(en)
|
2018-03-23 |
2024-02-01 |
Codiak Biosciences Inc |
Extracellular vesicles containing agonist-STING
|
|
WO2019185477A1
(en)
|
2018-03-27 |
2019-10-03 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds containing 2-aza-hypoxanthine or 6h-pytazolo[1,5-d][1,2,4]triazin-7-one as sting agonists
|
|
WO2019185476A1
(en)
|
2018-03-27 |
2019-10-03 |
Boehringer Ingelheim International Gmbh |
Modified cyclic dinucleotide compounds
|
|
WO2019195063A1
(en)
|
2018-04-03 |
2019-10-10 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
KR102755259B1
(ko)
|
2018-04-03 |
2025-01-15 |
머크 샤프 앤드 돔 엘엘씨 |
Sting 효능제로서의 벤조티오펜 및 관련 화합물
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
*
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
TW202014193A
(zh)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
包含碳環核苷酸之2’3’－環二核苷酸
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
MA52754A
(fr)
|
2018-05-25 |
2021-04-14 |
Incyte Corp |
Composés hétérocycliques tricycliques en tant qu'activateurs de sting
|
|
WO2019232392A1
(en)
|
2018-06-01 |
2019-12-05 |
Eisai R&D Management Co., Ltd. |
Methods for the treatment of bladder cancer
|
|
JP7440504B2
(ja)
|
2018-07-10 |
2024-02-28 |
エフ－スター・セラピューティクス・インコーポレイテッド |
疾患を治療するための化合物、組成物及び方法
|
|
US10875872B2
(en)
|
2018-07-31 |
2020-12-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
US11008344B2
(en)
|
2018-07-31 |
2021-05-18 |
Incyte Corporation |
Tricyclic heteroaryl compounds as STING activators
|
|
EP3837268B1
(en)
*
|
2018-08-16 |
2025-01-15 |
Eisai R&D Management Co., Ltd. |
Salts of compounds and crystals thereof
|
|
EP3841112A1
(en)
|
2018-08-24 |
2021-06-30 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting dendritic cells and uses thereof
|
|
IL315138A
(en)
|
2018-09-06 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
|
|
CA3113425A1
(en)
*
|
2018-09-21 |
2020-03-26 |
Shanghai De Novo Pharmatech Co., Ltd. |
Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
|
|
US11110106B2
(en)
|
2018-10-29 |
2021-09-07 |
Venenum Biodesign, LLC |
Sting agonists for treating bladder cancer and solid tumors
|
|
AU2019371206A1
(en)
|
2018-10-29 |
2021-05-27 |
Venenum Biodesign, LLC |
Novel sting agonists
|
|
WO2020092617A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody conjugates comprising sting agonists
|
|
US11596692B1
(en)
|
2018-11-21 |
2023-03-07 |
Incyte Corporation |
PD-L1/STING conjugates and methods of use
|
|
US12129267B2
(en)
|
2019-01-07 |
2024-10-29 |
Incyte Corporation |
Heteroaryl amide compounds as sting activators
|
|
EP3935065A1
(en)
*
|
2019-03-07 |
2022-01-12 |
Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
CA3129022C
(en)
|
2019-03-07 |
2023-08-01 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
CA3129011C
(en)
*
|
2019-03-07 |
2023-12-19 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
AU2020240135A1
(en)
|
2019-03-21 |
2021-10-14 |
Lonza Sales Ag |
Extracellular vesicles for vaccine delivery
|
|
AU2020241903A1
(en)
|
2019-03-21 |
2021-10-14 |
Lonza Sales Ag |
Extracellular vesicle conjugates and uses thereof
|
|
EP3946324B1
(en)
|
2019-04-04 |
2025-07-30 |
Merck Sharp & Dohme LLC |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
WO2020227421A1
(en)
|
2019-05-09 |
2020-11-12 |
Aligos Therapeutics, Inc. |
Modified cyclic dinucleoside compounds as sting modulators
|
|
PH12021552853A1
(en)
|
2019-05-10 |
2022-10-24 |
Takeda Pharmaceuticals Co |
Antibody drug conjugates
|
|
EP3994158A1
(en)
|
2019-07-03 |
2022-05-11 |
Codiak BioSciences, Inc. |
Extracellular vesicles targeting t cells and uses thereof
|
|
EP3993834A1
(en)
|
2019-07-05 |
2022-05-11 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
RS66126B1
(sr)
*
|
2019-07-22 |
2024-11-29 |
Lupin Ltd |
Makrociklična jedinjenja kao agonisti uboda i njihove metode i upotreba
|
|
EP4003325A1
(en)
|
2019-07-24 |
2022-06-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of the sting pathway for the treatment of hidradenitis suppurativa
|
|
JP2022543086A
(ja)
|
2019-08-02 |
2022-10-07 |
メルサナ セラピューティクス インコーポレイテッド |
がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物
|
|
US12098212B2
(en)
|
2019-08-12 |
2024-09-24 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
|
CN110590888B
(zh)
*
|
2019-09-10 |
2022-10-28 |
山东大学 |
一种应用sting蛋白亲合纯化环二核苷酸的方法
|
|
JP2022549328A
(ja)
|
2019-09-25 |
2022-11-24 |
コディアック バイオサイエンシーズ， インコーポレイテッド |
細胞外小胞組成物
|
|
EP4034247A1
(en)
|
2019-09-25 |
2022-08-03 |
Codiak BioSciences, Inc. |
Sting agonist comprising exosomes for treating neuroimmunological disorders
|
|
WO2021062290A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Methods of producing extracellular vesicles
|
|
CA3152488A1
(en)
|
2019-09-25 |
2021-04-01 |
Codiak Biosciences, Inc. |
Combination therapy using extracellular vesicles
|
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
|
US20230074558A1
(en)
|
2019-12-06 |
2023-03-09 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
JP7662644B2
(ja)
|
2019-12-18 |
2025-04-15 |
シーティーエックスティー・ピーティーワイ・リミテッド |
化合物
|
|
US12251449B2
(en)
|
2019-12-19 |
2025-03-18 |
William Marsh Rice University |
Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
|
|
CN115209921B
(zh)
|
2020-03-06 |
2025-06-24 |
第一三共株式会社 |
包含环状二核苷酸衍生物的抗体药物偶联物
|
|
US20230114434A1
(en)
|
2020-03-13 |
2023-04-13 |
Codiak Biosciences, Inc. |
Extracellular vesicles for treating neurological disorders
|
|
EP4121450A2
(en)
|
2020-03-20 |
2023-01-25 |
Codiak BioSciences, Inc. |
Extracellular vesicles for therapy
|
|
JP2023520513A
(ja)
|
2020-04-02 |
2023-05-17 |
メルサナ セラピューティクス インコーポレイテッド |
Ｓｔｉｎｇアゴニストを含む抗体薬物コンジュゲート
|
|
WO2021206158A1
(ja)
|
2020-04-10 |
2021-10-14 |
小野薬品工業株式会社 |
がん治療方法
|
|
AU2021270750B2
(en)
|
2020-05-13 |
2024-06-13 |
Massachusetts Institute Of Technology |
Compositions of polymeric microdevices and their use in cancer immunotherapy
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
CN111956797B
(zh)
*
|
2020-07-10 |
2022-05-13 |
清华大学 |
新型疫苗佐剂及其在新冠肺炎疫苗和其他疫苗中的应用
|
|
EP4192506A1
(en)
|
2020-08-07 |
2023-06-14 |
Tambo, Inc. |
Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
|
|
CA3191395A1
(en)
|
2020-09-02 |
2022-03-10 |
Daiichi Sankyo Company, Limited |
Novel endo-.beta.-n-acetylglucosaminidase
|
|
EP4216993A2
(en)
|
2020-09-23 |
2023-08-02 |
Codiak BioSciences, Inc. |
Methods of producing extracellular vesicles
|
|
WO2022066883A1
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Extracellular vesicles comprising kras antigens and uses thereof
|
|
US20220168330A1
(en)
|
2020-11-09 |
2022-06-02 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
|
US20220211883A1
(en)
|
2020-12-17 |
2022-07-07 |
Trustees Of Tufts College |
Fap-activated radiotheranostics and uses related thereto
|
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體－免疫賦活化劑共軛物之新穎製造方法
|
|
WO2022223619A1
(en)
|
2021-04-20 |
2022-10-27 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
JP2024517131A
(ja)
|
2021-04-20 |
2024-04-19 |
アンスティテュ・クリー |
免疫療法における使用のための組成物及び方法
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
WO2023056468A1
(en)
|
2021-09-30 |
2023-04-06 |
Codiak Biosciences, Inc. |
Extracellular vesicle comprising cholesterol tagged sting-agonist
|
|
US20250243277A1
(en)
|
2021-10-07 |
2025-07-31 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
|
EP4488378A1
(en)
|
2022-03-02 |
2025-01-08 |
Daiichi Sankyo Company, Limited |
Method for producing fc-containing molecule
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
KR20250054799A
(ko)
|
2022-08-29 |
2025-04-23 |
다이이찌 산쿄 가부시키가이샤 |
변이 Fc 영역을 포함하는 항체 약물 콘쥬게이트
|
|
WO2024211577A1
(en)
|
2023-04-05 |
2024-10-10 |
Massachusetts Institute Of Technology |
Hybrid polymeric systems and methods of use thereof
|
|
WO2025262266A1
(en)
|
2024-06-21 |
2025-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Methods of determining the clinical phenotype of patients suffering from hidradenitis suppurativa
|
|
WO2026027944A1
(en)
|
2024-07-30 |
2026-02-05 |
Sairopa B.V. |
Anti-sirp alpha antibody formulations and uses thereof
|